Skip to content
  • Sunday, 26 July 2026
  • 3:02 am
  • Follow Us
Lab DB
  • Home
  • About Us
    • About Us
    • Affiliate Disclosure
    • Cookie Policy
    • Disclaimer
    • Privacy Policy
    • DMCA
    • Terms of Service
  • Contact Us
  • FAQ
  • Home
  • Vedana Therapeutics Secures $46 Million Series A to Advance Next-Generation Migraine Prevention Therapies Targeting PACAP
Pharmaceutical R&D

Vedana Therapeutics Secures $46 Million Series A to Advance Next-Generation Migraine Prevention Therapies Targeting PACAP

Teuku Ryan Jun 17, 2026 0

Seattle-based biotech firm Vedana Therapeutics has successfully closed a $46 million Series A financing round, a significant infusion of capital…

Read More
Pharmaceutical R&D

European Commission Approves AbbVie’s Aquipta (atogepant) for Acute Migraine Treatment

Teuku Ryan Jun 3, 2026 0

AbbVie has secured a significant regulatory endorsement from the European Commission (EC) for Aquipta (atogepant), marking a pivotal expansion of…

Read More
Restoring Mitochondrial Health Offers New Paradigm for Treating Chronic Nerve Pain and Diabetic NeuropathyThe 2026 ABRF Annual Meeting Forges Connections and Charts Future for Biomolecular Resource Facilities in PittsburghGilead Sciences Reports Robust Q1 2026 Performance Driven by Strong HIV Portfolio and Promising PrEP LaunchesIcy Environments May Have Catalyzed the Emergence of Life Through Freeze-Thaw Cycles, New Research Suggests
MEDVi Under Scrutiny: AI-Powered Telehealth Startup Faces FDA Warnings, Deceptive Marketing Allegations, and Multiple Lawsuits Despite Meteoric GrowthLLMOps in 2026: The 10 Tools Every Team Must HaveJapan’s FY26 NHI Drug Price Revision: Deeper Dive into Mechanisms and Market ImpactThe Most Favored Nation (MFN) Policy’s Unforeseen Ripple Effect: European Pharmaceutical Launches and Withdrawals Plummet
Remepy, a startup that pairs drugs with AI-driven apps, clears a Phase IIa test in Parkinson’sKing’s College London Researchers Identify Potential Breakthrough Alzheimer’s Treatment Through Repurposed Spinal Cord Injury Drug KCL-286Living Plastics That Self-Destruct: Scientists Engineer Microbe-Embedded Polymers for Complete and Rapid DecompositionSanofi Discontinues Amlitelimab Development in Atopic Dermatitis, Citing Lack of Meaningful Differentiation
YOU MAY HAVE MISSED
Laboratory Automation & Robotics
Remepy, a startup that pairs drugs with AI-driven apps, clears a Phase IIa test in Parkinson’s
Lana Keisha Jul 25, 2026
Neuroscience & Brain Research
King’s College London Researchers Identify Potential Breakthrough Alzheimer’s Treatment Through Repurposed Spinal Cord Injury Drug KCL-286
Rifan Muazin Jul 25, 2026
Advanced Materials Science
Living Plastics That Self-Destruct: Scientists Engineer Microbe-Embedded Polymers for Complete and Rapid Decomposition
Nila Kartika Wati Jul 25, 2026
Pharmaceutical R&D
Sanofi Discontinues Amlitelimab Development in Atopic Dermatitis, Citing Lack of Meaningful Differentiation
Teuku Ryan Jul 25, 2026

Copyright © 2025 | Powered by WordPress | News Gadgets by ThemeArile

  • Home
  • About Us
    • About Us
    • Affiliate Disclosure
    • Cookie Policy
    • Disclaimer
    • Privacy Policy
    • DMCA
    • Terms of Service
  • Contact Us
  • FAQ